SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ:INVA) today announced that Michael W.
Aguiar, Innoviva's President and Chief Executive Officer, will be
presenting at two conferences in early September as follows:
Wells Fargo Healthcare Conference
Westin Waterfront, Boston
Wednesday,
September 7 at 8:45 a.m. ET
Webcast Link (archived for 90 days): Wells
Fargo Innoviva Webcast
Baird Global Healthcare Conference
New York Palace Hotel, New York
Thursday,
September 8 at 9:05 a.m. ET
Webcast Link (archived for 90 days): Baird
Innoviva Webcast
About Innoviva
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®
and, if approved and commercialized, VI monotherapy, as well. In
addition, Innoviva retains a 15 percent economic interest in future
payments made by GSK for earlier-stage programs partnered with
Theravance BioPharma, Inc. For more information, please visit Innoviva's
website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005092/en/
Innoviva, Inc.
Eric d'Esparbes, 650-238-9640
Senior Vice
President and Chief Financial Officer
investor.relations@inva.com
Source: Innoviva, Inc.
News Provided by Acquire Media